Back to Agenda
Session 2: Development Strategies That Consider The Health Care Setting in Each Country
Session Chair(s)
E. Stewart Geary, MD
MD, Global Safety Officer
Eisai Co., Ltd., Japan
Yoshihiko Ono, RPh
Regulatory Executive Advisor, Japan Development
MSD K.K., Japan
The ultimate goal of clinical development is to make medical products available to patients as soon as safety and efficacy have been confirmed. Despite recent success in speeding data collection and early approval through global clinical trials in recent years, this goal will only be half met if patients are not able to get access to new products in daily medical practice. Although we need to have a comprehensive understanding of the broad medical environment surrounding health care services such as health insurance and drug pricing in each country in order to supply products smoothly, there is still insufficient discussion about the differences in health care systems as they relate to access to medicines compared with topics directly associated with regulatory approval such as ethnic differences. This session will provide an opportunity for exchanging opinions on differences in the broad health care environment in China, Korea, and Taiwan and have a constructive discussion about development strategies that speed the access of patients to medicines.
Speaker(s)
Overview
Koichi Miyazaki, PhD
Daiichi Sankyo Co., Ltd., Japan
Senior Director, Group IV, Oncology Clinical Development Department
The reform of health care system and medical administration in China
Yutaka Masada
Beijing Rifengtaida International Medical Technology Consulting Company, Japan
CEO
The broad health care environment in Korea
Masashi Fukuyama
Kyowa Hakko Kirin Co., Ltd., Japan
Director, External Relations Department
Development strategies that consider the healthcare policy in Taiwan
Jackie Tieng
Takeda Pharmaceuticals Taiwan Ltd., Taiwan
Head of Marketing
Have an account?